// App-Quantinova.ai

e17029 : DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Researchers

Presenter

  • Evan Y. Yu

Principal Investigators

  • Christopher Michael Pieczonka

  • Andrew J. Armstrong

  • Hiroyoshi Suzuki

  • James L. Bailen

  • Declan G. Murphy

  • Thierry Lebret

  • Murilo Luz

  • Antoine Thiery-Vuillemin

  • Jorge A. Ortiz

  • Javeed Khan

  • Alberto Briganti

Medical Centers

  • University of Washington, Seattle, WA

  • Associated Medical Professionals of NY, PLLC, Syracuse, NY

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • Toho University Sakura Medical C, Kashiwa-City, Japan

  • First Urology Research, Louisville, KY

  • University of Melbourne Peter MacCallum Cancer Center, Melbourne, Australia.

  • Hôpital Foch, Universite Versailles, St Quentin, Paris Saclay, Versailles, France

  • Hospital Erasto Gaertner, Curitiba, Brazil

  • Medical Oncology, Centre Hospitalier Régional Universitaire, Besancon, France

  • Imclone Syst Inc, Miami, FL

  • Bayer, Reading, United Kingdom.

  • Urological Research Institute, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy

Locations

  • United States

  • Japan

  • Australia

  • France

  • Brazil

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Observational

  • Non Interventional

  • Single Arm

  • Multinational

Phase

  • III

Study Id's

  • NCT02200614

  • NCT04122976

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved